pipeline
Therapeutic Area
Hematology
| Pre-IND | PhaseI / II | Phase III | Registration | Marketed |
|---|---|---|---|---|
| BESREMi® (ropeginterferon alfa-2b-njft) | ||||
PV | ||||
/ US, TW, KR, JP, CN, MY, SG, BR | ||||
/ HK AR, MX, CO, VN | ||||
| Ropeginterferon alfa-2b (P1101) | ||||
ET | ||||
PMF | ||||
Adult T-cell Leukemias | ||||
Therapeutic Area
SOLID TUMOR & IMMUNOLOGY
| Pre-IND | PhaseI / II | Phase III | Registration | Marketed |
|---|---|---|---|---|
| Ropeg + anti PD-1 | ||||
HCC | ||||
| PEG-IL-2 (P11838) | ||||
Immunology | ||||
| PEG-Cytokines | ||||
Solid tumors | ||||
| PD-1-IL-2v | ||||
/ - | ||||
| ADC (novel target) | ||||
/ - | ||||
| ADCS | ||||
/ - | ||||
| NY-ESO-1 TCR-T | ||||
/ - | ||||
| Novel TCR-T | ||||
/ - | ||||